Plato Investment Management Ltd Increases Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Plato Investment Management Ltd raised its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 103.8% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 15,493 shares of the medical device company’s stock after purchasing an additional 7,890 shares during the quarter. Plato Investment Management Ltd’s holdings in DexCom were worth $1,209,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Blue Whale Capital LLP boosted its position in DexCom by 91.9% during the 3rd quarter. Blue Whale Capital LLP now owns 236,000 shares of the medical device company’s stock valued at $15,821,000 after buying an additional 113,000 shares during the period. Brooktree Capital Management purchased a new stake in DexCom during the 3rd quarter valued at $683,000. National Pension Service boosted its position in DexCom by 4.1% during the 3rd quarter. National Pension Service now owns 949,743 shares of the medical device company’s stock valued at $63,671,000 after buying an additional 37,363 shares during the period. Intact Investment Management Inc. purchased a new stake in shares of DexCom in the 3rd quarter worth about $650,000. Finally, Motley Fool Asset Management LLC lifted its position in shares of DexCom by 168.7% in the 3rd quarter. Motley Fool Asset Management LLC now owns 272,622 shares of the medical device company’s stock worth $17,993,000 after purchasing an additional 171,150 shares during the period. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Stock Down 2.7 %

NASDAQ:DXCM opened at $85.99 on Tuesday. The firm has a market cap of $33.60 billion, a P/E ratio of 60.13, a P/E/G ratio of 2.30 and a beta of 1.14. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The firm has a 50-day simple moving average of $84.82 and a two-hundred day simple moving average of $76.85.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. Baird R W raised shares of DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Canaccord Genuity Group raised their target price on shares of DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a research report on Friday, February 14th. Robert W. Baird raised shares of DexCom from a “neutral” rating to an “outperform” rating and raised their target price for the stock from $86.00 to $104.00 in a research report on Thursday, January 16th. Wells Fargo & Company raised their target price on shares of DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. Finally, Redburn Atlantic raised shares of DexCom from a “neutral” rating to a “buy” rating and raised their target price for the stock from $85.00 to $115.00 in a research report on Monday, February 3rd. Four research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $99.06.

Insider Buying and Selling at DexCom

In other news, EVP Jereme M. Sylvain sold 2,090 shares of DexCom stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $181,641.90. Following the completion of the sale, the executive vice president now directly owns 83,526 shares in the company, valued at $7,259,244.66. The trade was a 2.44 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Kevin R. Sayer sold 33,359 shares of DexCom stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the completion of the sale, the chief executive officer now owns 319,037 shares of the company’s stock, valued at $27,727,505.67. This represents a 9.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 38,083 shares of company stock worth $3,309,794. 0.30% of the stock is owned by corporate insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.